Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A brief presentation is given of granulocyte physiology, as well as some techniques in use for assessing the adherance, the migration, the uptake and bacterial killing and finally the metabolic activity of these cells. Also the activities of the reticuloendothelial system and an in vivo method to measure the phagocytic and metabolic function of macrophages are described. A change, most often a decrease, in phagocytic function has been noted in several circumstances common in surgical practice. So is the case after open heart surgery, during infusion with colloids for blood replacement, and during treatment with immunosuppressive drugs. Further, various forms of malnutrition, such as total starvation, obesity and the hypertriglyceridemia following excessive infusion of fat emulsions may impair granulocyte function.
 ...
PMID:Phagocyte function in various situations in surgery. 27 40

Food deprivation is known to suppress antimicrobial defence under certain conditions. This potentially negative consequence of weight reduction treatment for obesity was studied in 11 obese patients who were treated with a mixed, balanced 600 kcal(2.5MJ)/day diet for 4 weeks. The mean body weight fell from 103 +/- 5 to 95 +/- 6 kg. The antimicrobial defence was studied before and during the diet period by analyses of polymorphonuclear granulocyte bactericidal capacity and adherence. No signs of impaired granulocyte function were found. The possibility remains that during prolonged treatment by semistarvation host defence may be impaired, especially in grossly obese patients whose antimicrobial defence may be already impaired before treatment.
 ...
PMID:Granulocyte functions during treatment of obesity. 52 23

20 obese subjects were compared with 20 controls with normal weight regarding their polymorphonuclear (PMN) granulocyte functions, and plasma lipids. The obese subjects showed a significantly decreased PMN bactericidal capacity, and increased PMN adherence. No differences were found in their mean PMN chemotaxis and opsonic capacity of plasma. The values of plasma triglycerides and free fatty acids were higher in the obese, while plasma cholesterol and phospholipids corresponded to the control values. The changes in granulocyte function did not correlate significantly to plasma lipid levels or to body weight and Broca's index in either group. --It is concluded that changes in granulocyte function occur in obesity, but are not related to plasma lipids or degree of overweight.
 ...
PMID:Obesity, plasma lipids and polymorphonuclear (PMN) granulocyte functions. 90 68

Growth hormone (GH), which has been extracted from the pituitary gland since early times, has become easily available by the advance of genetic engineering in recent year. Its clinical application to treatment in various fields, involving obesity, wounds, fractures, gastric ulcers and so on, is being increasingly discussed. The presence or absence of the effect of GH on leukopoiesis was studied in vivo and in vitro experiments. In the in vivo experiment, GH was administered to rats whose bone marrow production had been suppressed by the injection of mitomycin C, and time-course changes in the peripheral blood leukocyte count in these rats were compared with those in rats given physiological saline solution alone (control group). The in vitro experiment was performed by colony assay of mouse marrow cells. Insulin growth factor-1 (IGF-1) was also studied in the in vitro experiment. The in vivo experiment revealed that GH promoted recovery of leukocytes from the nadir, and in the in vitro experiments GH and IGF-1 were demonstrated to increase the number of colonies in the presence of granulocyte macrophage colony stimulating factor (GM-CSF). GH was considered to exert effects on myeloid progenitor cells and the hemopoietic microenvironment simultaneously, resulting in an increase in leukocytes.
 ...
PMID:[The effect of growth hormone on leukopoiesis: in vivo and in vitro studies]. 188 15

The influence of obesity and a decrease of the body weight in the patients, treated with low-caloric diet, on several indices of cellular immunity has been studied. Absolute and relative T- and B-lymphocyte content, monocyte lysosome content and granulocyte phagocytic activity were examined in the peripheral blood of 27 obese patients and 30 normal subjects. Reversible inhibition of cellular immunity was revealed in the obese patients. The body weight lowering, which resulted from the treatment of obese patients with a low-caloric diet, promoted returning their immunity to normal.
 ...
PMID:[Various indicators of cellular immunity in obesity. Effect of low-calorie diet]. 697 63

The possible influence on blood polymorphonuclear (PMN) granulocyte functions of the small intestinal shunt operation for obesity was studied in 10 massively overweight patients. They were investigated prior to operation and for 9 months afterwards, when they had lost an average of 32 kg body weight. Preoperatively they showed reduced PMN bactericidal capacity and increased PMN adherence compared with controls of normal weight. During the first 2--4 months postoperatively all patients displayed a gradually increasing bactericidal capacity, which then reached levels similar to the controls and remained so for the rest of the follow-up period. This enhancement was more easily assessed by a new in vitro assay in which each PMN was provided with 30--40 bacteria, than by a standard assay using 2--4 bacteria per granulocyte. PMN adherence decreased during the first postoperative months and then returned to preoperative levels. The changes in PMN functions were not statistically related either to each other or to the continuous loss of body wieght. Thus, impairment of PMN killing function occurring in extremely obese patients became normalized after small bowel shunt operation, while the high adherence remained unchanged.
 ...
PMID:Polymorphonuclear (PMN) function after small intestinal shunt operation for morbid obesity. 737 87

Previous studies have shown that the small-bowel shunt operation for morbid obesity may be followed by signs of enhanced cell-mediated immunity and polymorphonuclear (PMN) granulocyte bactericidal capacity. In the present study seven patients, operated 4 months--4.5 years previously and exhibiting postoperative arthralgias, arthritis, and/or skin rashes, were investigated with regard to their PMN adherence and bactericidal capacity and plasma levels of complement factors 3 and 4 (C3 and C4). There patients showed a decreased PMN bactericidal capacity compared both with 10 other shunt-operated patients without skin and joint symptoms and with healthy controls, whereas PMN adherence was lower than for the non-symptomatic patients but similar to that of the controls. Two patients had C3 levels above the reference value; all had normal C4 values. Thus, a small-bowel shunt operation for obesity, complicated by skin and joint symptoms, might be associated with decreased PMN bactericidal capacity.
 ...
PMID:Polymorphonuclear function in patients with skin and joint symptoms after small-intestinal shunt operations. 743 90

The ob gene product, leptin, has been shown in several studies to be involved in weight control and recombinant leptin recently has entered clinical trials to treat obesity. The leptin receptor (OB-R/B219) is expressed in a variety of protein isoforms not only in the central nervous system, but also in reproductive, and hematopoietic tissues. We reported recently that the OB-R/B219 was associated with a variety of hematopoietic lineages as well as the small fraction of cells containing the long-term reconstituting hematopoietic stem cells. Herein we report that leptin significantly stimulates the proliferation and differentiation of yolk sac cells and fetal liver cells and stimulates directly hematopoietic precursors. Leptin alone can increase the number of macrophage and granulocyte colonies, and leptin plus erythropoietin act synergistically to increase erythroid development. These data show that leptin has a significant, direct effect on early hematopoietic development and can stimulate the differentiation of lineage-restricted precursors of the erythrocytic and myelopoietic lineages. These observations along with a recent report strongly support our previous hypothesis that leptin has an unanticipated important role in hematopoietic and immune system development.
 ...
PMID:Leptin stimulates fetal and adult erythroid and myeloid development. 937 66

Chemotaxis, spontaneous migration, phagocytosis, expression of the receptors of Fc Ig fragments and of C3 component of complement has been examined in blood of 51 patients with obesity divided into 3 groups with: 1. disturbances in carbohydrate and lipid metabolism, 2. disturbance in lipid metabolism, 3. no symptoms of metabolic diseases and 20 healthy controls. A comparison of the characteristics of neutral granulocytes in the blood of the healthy controls before and after fat rich meal has been performed. Obtained results indicate that high concentration of lipids, decrease granulocyte activity therefore could be the cause of the decrease of immunological defence.
 ...
PMID:[Examination of human neutrophil activation in hyperlipidemia]. 928 6

The Philadelphia chromosome-negative chronic myeloproliferative disorders (CMPD), polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (IMF), have overlapping clinical features but exhibit different natural histories and different therapeutic requirements. Phenotypic mimicry amongst these disorders and between them and nonclonal hematopoietic disorders, lack of clonal diagnostic markers, lack of understanding of their molecular basis and paucity of controlled, prospective therapeutic trials have made the diagnosis and management of PV, ET and IMF difficult. In Section I, Dr. Jerry Spivak introduces current clinical controversies involving the CMPD, in particular the diagnostic challenges. Two new molecular assays may prove useful in the diagnosis and classification of CMPD. In 2000, the overexpression in PV granulocytes of the mRNA for the neutrophil antigen NBI/CD177, a member of the uPAR/Ly6/CD59 family of plasma membrane proteins, was documented. Overexpression of PRV-1 mRNA appeared to be specific for PV since it was not observed in secondary erythrocytosis. At this time, it appears that overexpression of granulocyte PRV-1 in the presence of an elevated red cell mass supports a diagnosis of PV; absence of PRV-1 expression, however, should not be grounds for excluding PV as a diagnostic possibility. Impaired expression of Mpl, the receptor for thrombopoietin, in platelets and megakaryocytes has been first described in PV, but it has also been observed in some patients with ET and IMF. The biologic basis appears to be either alternative splicing of Mpl mRNA or a single nucleotide polymorphism, both of which involve Mpl exon 2 and both of which lead to impaired posttranslational glycosylation and a dominant negative effect on normal Mpl expression. To date, no Mpl DNA structural abnormality or mutation has been identified in PV, ET or IMF. In Section II, Dr. Tiziano Barbui reviews the best clinical evidence for treatment strategy design in PV and ET. Current recommendations for cytoreductive therapy in PV are still largely similar to those at the end of the PVSG era. Phlebotomy to reduce the red cell mass and keep it at a safe level (hematocrit < 45%) remains the cornerstone of treatment. Venesection is an effective and safe therapy and previous concerns about potential side effects, including severe iron deficiency and an increased tendency to thrombosis or myelofibrosis, were erroneous. Many patients require no other therapy for many years. For others, however, poor compliance to phlebotomy or progressive myeloproliferation, as indicated by increasing splenomegaly or very high leukocyte or platelet counts, may call for the introduction of cytoreductive drugs. In ET, the therapeutic trade-off between reducing thrombotic events and increasing the risk of leukemia with the use of cytoreductive drugs should be approached by patient risk stratification. Thrombotic deaths seem very rare in low-risk ET subjects and there are no data indicating that fatalities can be prevented by starting cytoreductive drugs early. Therefore, withholding chemotherapy might be justifiable in young, asymptomatic ET patients with a platelet count below 1500000/mm(3) and with no additional risk factors for thrombosis. If cardiovascular risk factors together with ET are identified (smoking, obesity, hypertension, hyperlipidemia) it is wise to consider platelet-lowering agents on an individual basis. In Section III, Dr. Gianni Tognoni discusses the role of aspirin therapy in PV based on the recently completed European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Study, a multi-country, multicenter project aimed at describing the natural history of PV as well as the efficacy of low-dose aspirin. Aspirin treatment lowered the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (relative risk 0.41 [95% CI 0.15-1.15], P =.0912). Total and cardiovascular mortality were also reduced by 46% and 59%, respectively. Major bleedings were slightly increased nonsignificnsignificantly by aspirin (relative risk 1.62, 95% CI 0.27-9.71). In Section IV, Dr. Giovanni Barosi reviews our current understanding of the pathophysiology of IMF and, in particular, the contributions of anomalous megakaryocyte proliferation, neoangiogenesis and abnormal CD34(+) stem cell trafficking to disease pathogenesis. The role of newer therapies, such as low-conditioning stem cell transplantation and thalidomide, is discussed in the context of a general treatment strategy for IMF. The results of a Phase II trial of low-dose thalidomide as a single agent in 63 patients with myelofibrosis with meloid metaplasia (MMM) using a dose-escalation design and an overall low dose of the drug (The European Collaboration on MMM) will be presented. Considering only patients who completed 4 weeks of treatment, 31% had a response: this was mostly due to a beneficial effect of thalidomide on patients with transfusion dependent anemia, 39% of whom abolished transfusions, patients with moderate to severe thrombocytopenia, 28% of whom increased their platelet count by more than 50 x 10(9)/L, and patients with the largest splenomegalies, 42% of whom reduced spleen size of more than 2 cm.
 ...
PMID:Chronic myeloproliferative disorders. 1463 83


1 2 3 4 Next >>